Preclinical studies and reviews highlight that repurposing available SGLT2 or SGLT1/SGLT2 inhibitors traditionally developed for diabetes mellitus management might be a novel option for cancer therapy (Vrhovac Madunić et al., 2018; Pandey et al., 2025), as some, such as empagliflozin, demonstrated promising results for cancer treatment (Wu et al., 2023; Eliaa et al., 2020). Here, SLC5A2 is linked to diabetes mellitus.